Quarterly report pursuant to Section 13 or 15(d)

Segments

v3.20.1
Segments
3 Months Ended
Mar. 31, 2020
Segment Reporting [Abstract]  
SEGMENTS SEGMENTS
We manage our operations in two reportable segments, pharmaceutical and diagnostics. The pharmaceutical segment consists of our pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, Rayaldee product sales and our pharmaceutical research and development. The diagnostics segment primarily consists of our clinical laboratory operations
through BioReference and our point-of-care operations. There are no significant inter-segment sales. We evaluate the performance of each segment based on operating profit or loss. There is no inter-segment allocation of interest expense and income taxes.
Information regarding our operations and assets for our operating segments and the unallocated corporate operations as well as geographic information are as follows:
 
For the three months ended March 31,
(In thousands)
2020
 
2019
Revenue from services:
 
 
 
Pharmaceutical
$

 
$

Diagnostics
170,839

 
178,891

Corporate

 

 
$
170,839

 
$
178,891

Revenue from products:
 
 
 
Pharmaceutical
$
31,074

 
$
25,301

Diagnostics

 

Corporate

 

 
$
31,074

 
$
25,301

Revenue from transfer of intellectual property and other:
 
 
 
Pharmaceutical
$
9,553

 
$
18,259

Diagnostics

 

Corporate

 

 
$
9,553

 
$
18,259

Operating loss:
 
 
 
Pharmaceutical
$
(14,126
)
 
$
(29,477
)
Diagnostics
(18,133
)
 
(33,569
)
Corporate
(8,503
)
 
(12,272
)
 
$
(40,762
)
 
$
(75,318
)
Depreciation and amortization:
 
 
 
Pharmaceutical
$
7,121

 
$
7,526

Diagnostics
14,871

 
16,271

Corporate
60

 
19

 
$
22,052

 
$
23,816

Loss from investment in investees:
 
 
 
Pharmaceutical
$
(134
)
 
$
(1,854
)
Diagnostics

 

Corporate

 

 
$
(134
)
 
$
(1,854
)
Revenues:
 
 
 
United States
$
180,872

 
$
184,894

Ireland
11,901

 
20,534

Chile
10,850

 
7,865

Spain
4,156

 
4,418

Israel
1,707

 
3,116

Mexico
1,841

 
1,531

Other
139


93

 
$
211,466

 
$
222,451


(In thousands)
March 31,
2020
 
December 31,
2019
Assets:
 
 
 
Pharmaceutical
$
1,157,430

 
$
1,174,639

Diagnostics
1,026,880

 
1,035,112

Corporate
48,232

 
99,521

 
$
2,232,542

 
$
2,309,272

Goodwill:

 

Pharmaceutical
$
234,773

 
$
237,131

Diagnostics
434,809

 
434,809

Corporate

 

 
$
669,582

 
$
671,940



No customer represented more than 10% of our total consolidated revenue during the three months ended March 31, 2020 and 2019. As of March 31, 2020 and December 31, 2019, no customer represented more than 10% of our accounts receivable balance.